Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytoma Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches

Laurent Yon (1) , Y. Anouar (1) , J. Guillemot (1) , E. Thouennon (1) , L. Barbier (1) , A. Gimenez-Roqueplo (2) , J. Bertherat (3) , H. Lefebvre (1) , M. Klein (4) , M. Muresan (4) , E. Grouzmann (2) , P.-F. Plouin (5) , H. Vaudry (1) , A. Elkahloun (6)

1 Neuroendocrinologie cellulaire et moléculaire
2 HEGP - Hôpital Européen Georges Pompidou [APHP]
3 UMR_S567 / UMR 8104 - Institut Cochin
4 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
5 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
6 NIH - National Institutes of Health [Bethesda, MD, USA]

Pheochromocytomas (PHEOs) are rare catecholamine-producing neoplasias that arise from chromaffin cells of the adrenal medulla or from extra-adrenal locations. These neuroendocrine tumors are usually benign, but may also present as or develop into a malignancy. There are currently no means to predict or to cure malignant tumors which have a poor prognosis. We have recently validated several assays for the measurement of peptides derived from chromogranin A (CgA) and secretogranin II (SgII) in order to determine whether these secreted neuroendocrine products could provide useful, complementary markers for the diagnosis and prognosis of PHEOs. Both the CgA-derived peptide WE14 and the SgII-derived peptide EM66 proved to be sensitive circulating markers for the diagnosis of PHEO. In addition, much higher EM66 levels were measured in benign than in malignant tumoral tissues, suggesting that this peptide could represent a valuable tool for the prognosis of PHEO. We have also initiated a comparative microarray study of benign and malignant PHEOs, which allowed the identification of a set of about 100 genes that were differentially expressed and best discriminated the two types of tumors. A large majority of these genes were expressed at lower levels in the malignant disease and were associated with various characteristics of chromaffin cells, such as hormone secretion signaling and machinery, peptide maturation, and cellular morphology. Altogether, these studies provide novel tools for the management of PHEO, and new insights for the understanding of tumorigenesis in chromaffin cells, which may offer potential therapeutic strategies.

Domaines: Sciences du Vivant [q-bio]

Laurent Yon, Y. Anouar, J. Guillemot, E. Thouennon, L. Barbier, et al.. Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytoma Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches. Annals of the New York Academy of Sciences, 2006, 1073 (1), pp.533 - 540. ⟨10.1196/annals.1353.057⟩. ⟨hal-01706439⟩